// App-Quantinova.ai

AB0444 (2022) : ENPATORAN: PRECLINICAL EVIDENCE SUPPORTING GLUCOCORTICOID DOSE REDUCTION AND PHASE II STUDY DESIGN IN PATIENTS WITH SLE AND/OR CLE (WILLOW)

Researchers

Presenter

  • E. F. Morand

Principal Investigators

  • A. Bender

  • A. Deshpande

  • B. Vaidyanathan

  • C. Vazquez Mateo

  • M. Przetak

  • F. Moreau

  • M. Khursheed

  • S. Roy

  • D. Pearson

Medical Centers

  • Centre for Inflammatory Diseases, Monash University, Melbourne, Australia

  • EMD Serono Research & Development Institute, Inc., an Affiliate of Merck KGaA, Global Biostatistics, Billerica, United States of America

  • EMD Serono Research & Development Institute, Inc., an Affiliate of Merck KGaA, Global Biostatistics, Billerica, United States of America

  • EMD Serono Research & Development Institute, Inc., an Affiliate of Merck KGaA, Global Biostatistics, Billerica, United States of America

  • Merck Serono Ltd., an Affiliate of Merck KGaA, Global Patient Safety, Feltham, United Kingdom

  • Ares Trading SA, an Affiliate of Merck KGaA, Global Clinical Development, Eysins, Switzerland

  • University of Minnesota, The Center for Immunology, Minneapolis, United States of America

Locations

  • Australia

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

  • Cytokine

Drug/Treatment

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT05162586

Sponsors

  • The Healthcare Business of Merck KGaA

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved